Clinical Scorecard: Prognostic Role of Pan-Immune-Inflammatory Value in Predicting Adverse Cardiovascular and Cerebrovascular Outcomes Following Percutaneous Coronary Intervention in Diabetic Patients with Coronary Heart Disease

At a Glance

Key Highlights

• PIV reflects systemic inflammatory and immune imbalance in diabetic coronary heart disease patients.
• Elevated pre-procedural PIV is associated with increased risk of adverse cardiovascular and cerebrovascular events after PCI.
• PIV demonstrated superior prognostic performance compared with conventional inflammatory indices.
• High PIV was associated with poorer long-term MACCE-free survival following coronary intervention.
• PIV may serve as a simple and cost-effective biomarker for individualized risk stratification in diabetic patients undergoing PCI.

Guideline-Based Recommendations

Diagnosis

• Diabetes mellitus diagnosis as per American Diabetes Association criteria.

Management

• PCI procedures conducted per European Society of Cardiology and American College of Cardiology guidelines.

Monitoring & Follow-up

• Follow-up for major adverse cardiovascular and cerebrovascular events (MACCE) post-PCI.

Risks

• Increased risk of MACCE in diabetic patients post-PCI, particularly with elevated PIV.

Patient & Prescribing Data

210 consecutive diabetics with coronary heart disease scheduled for PCI.

PIV serves as a prognostic biomarker for risk stratification in this population.

Clinical Best Practices

• Utilize PIV for risk stratification in diabetic patients undergoing PCI.
• Monitor inflammatory markers in conjunction with traditional risk factors.

Related Resources & Content

• Study on PIV and cardiovascular outcomes